Related content

The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option

By Gadducci Angiolo   Spirito Nicoletta   Baroni Elena   Tana Roberta   Genazzani Andrea Riccardo  

Gynecological Endocrinology, Vol. 25, Iss. 10, 2009-10 ,pp. : 683-691

Informa Healthcare

Access to resources Recommend Favorite

The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study

By Pashov Alexandr I.   Tskhay Vitaly B.   Ionouchene Svetlana V.  

Gynecological Endocrinology, Vol. 28, Iss. 7, 2012-07 ,pp. : 559-561

Informa Healthcare

Access to resources Recommend Favorite

Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome

By Kashyap Sonya  

Human Reproduction, Vol. 19, Iss. 11, 2004-11 ,pp. : 2474-2483

Oxford University Press

Access to resources Recommend Favorite

Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women: a report of six cases

By Fujiwara H.   Ogawa S.   Motoyama M.   Takei Y.   Machida S.   Taneichi A.   Ohwada M.   Suzuki M.  

Human Reproduction, Vol. 24, Iss. 5, 2009-05 ,pp. : 1045-1050

Oxford University Press

Access to resources Recommend Favorite

Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women

By Morelli Michele   Di Cello Annalisa   Venturella Roberta   Mocciaro Rita   D’Alessandro Pietro   Zullo Fulvio  

Gynecological Endocrinology, Vol. 29, Iss. 2, 2013-02 ,pp. : 156-159

Informa Healthcare

Access to resources Recommend Favorite